早期单剂外泌体治疗在猪创伤性脑损伤与失血性休克模型中提供神经保护并改善血脑屏障完整性
该研究在雌性约克夏猪中建立重型创伤性脑损伤(12毫米皮质撞击)与失血性休克(估计总血容量的40%)模型,在休克1小时时将动物随机分为乳酸林格液组(5 mL)或乳酸林格液+外泌体组(1×10外泌体颗粒溶于5 mL乳酸林格液),每组5只。继续休克1小时后行生理盐水复苏,观察6小时。结果显示外泌体治疗组脑肿胀显著减轻、病灶尺寸显著缩小、颅内压显著降低、脑灌注压显著升高,白蛋白外渗显著减少,层粘连蛋白、claudin-5和闭锁小带蛋白1水平显著升高,血清胶质纤维酸性蛋白水平显著降低。作者结论认为早期单剂间充质干细胞来源外泌体治疗可减轻脑肿胀和病灶大小、降低血液脑损伤生物标志物水平并改善血脑屏障完整性。
要点
- 在猪创伤性脑损伤合并失血性休克模型中,休克后1小时单剂间充质干细胞来源外泌体(1×10外泌体颗粒溶于5 mL乳酸林格液)治疗组较乳酸林格液对照组脑肿胀显著减轻(p<0.05)。
- 外泌体治疗组病灶尺寸显著小于对照组(p<0.05),颅内压显著降低、脑灌注压显著升高(p<0.05)。
- 外泌体治疗组白蛋白外渗显著减少,层粘连蛋白、claudin-5和闭锁小带蛋白1水平显著升高(p<0.05),提示血脑屏障完整性改善。
- 实验结束时外泌体治疗组血清胶质纤维酸性蛋白水平显著低于对照组(p<0.05)。
- 该研究为大型动物模型,每组5只,结果需在临床研究中进一步验证。
适用人群与场景
- 雌性约克夏猪,重型创伤性脑损伤(12毫米皮质撞击)合并失血性休克(估计总血容量的40%)。
处置流程与药物剂量
- 休克后1小时随机给予乳酸林格液5 mL(对照组)或乳酸林格液+外泌体1×10外泌体颗粒溶于5 mL乳酸林格液(治疗组)。
- 继续休克1小时后行生理盐水复苏,观察6小时。
研究设计与关键结果
- 研究类型:大型动物(猪)随机对照实验,每组5只。
- 干预与对照:休克后1小时单剂间充质干细胞来源外泌体(1×10外泌体颗粒溶于5 mL乳酸林格液) vs 乳酸林格液5 mL。
- 主要终点:外泌体治疗组脑肿胀和病灶尺寸显著小于对照组(p<0.05)。
- 关键次要终点:外泌体治疗组颅内压显著降低、脑灌注压显著升高(p<0.05);白蛋白外渗显著减少,层粘连蛋白、claudin-5和闭锁小带蛋白1水平显著升高(p<0.05);血清胶质纤维酸性蛋白水平显著降低(p<0.05)。
证据类型、等级与局限
- 证据类型:动物实验(猪模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在创伤性脑损伤合并失血性休克的大型动物模型中,早期单剂间充质干细胞来源外泌体治疗可减轻脑肿胀和病灶大小、降低血液脑损伤生物标志物水平并改善血脑屏障完整性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Administration of human mesenchymal stem cell (MSC)-derived exosomes can enhance neurorestoration in models of traumatic brain injury (TBI) and hemorrhagic shock (HS). The impact of early treatment with MSC-derived exosomes on brain injury in a large animal model remains unknown. We sought to evaluate the impact of early single-dose exosome treatment on brain swelling and lesion size, blood-based cerebral biomarkers, and blood-brain barrier (BBB) integrity.
METHODS: Female Yorkshire swine were subjected to a severe TBI (12-mm cortical impact) and HS (40% estimated total blood volume). One hour into shock, animals were randomized (n = 5/cohort) to receive either lactated Ringer's (LR; 5 mL) or LR + exosomes (1 × 10 exosome particles in 5 mL LR). Animals then underwent additional shock (1 hour) followed by normal saline resuscitation. After 6 hours of observation, brain swelling (% increase compared with the uninjured side) and lesion size (mm) were assessed. Cerebral hemodynamics and blood-based biomarkers of brain injury were compared. Immunofluorescence and RNA sequencing with differential gene expression and pathway analysis were used to assess the integrity of the perilesion BBB.
RESULTS: Exosome-treated animals had significantly less (p < 0.05) brain swelling and smaller lesion size. They also had significantly decreased (p < 0.05) intracranial pressures and increased cerebral perfusion pressures. Exosome-treated animals had significantly decreased (p < 0.05) albumin extravasation and significantly higher (p < 0.05) laminin, claudin-5, and zonula occludens 1 levels. Differential gene expression and pathway analysis confirmed these findings. Serum glial fibrillary acidic protein levels were also significantly lower (p < 0.05) in the exosome-treated cohort at the end of the experiment.
CONCLUSION: In a large animal model of TBI and HS, early treatment with a single dose of MSC-derived exosomes significantly attenuates brain swelling and lesion size, decreases levels of blood-based cerebral biomarkers, and improves BBB integrity.
参考来源
- Williams AM, Bhatti UF, Brown JF, et al. Early single-dose treatment with exosomes provides neuroprotection and improves blood-brain barrier integrity in swine model of traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2020. PMID: 31804413. doi:10.1097/TA.0000000000002563
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。